Company: NCEL
Filing Date: 2025-02-10
Form Type: 425
Source: 0001213900-25-011502
Chunk: 5

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: 425
Chunk 5
---
 companies; inability to timely develop and introduce new technologies, products and applications; and loss of market share
and pressure on pricing resulting from competition, which could cause the actual results or performance of candidate products to differ
materially from those contemplated in such forward-looking statements. Except as otherwise required by law, neither Kadimastem nor NLS
undertakes any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting
NLS is contained under the heading “Risk Factors” in NLS’s annual report on Form 20-F for the year ended December 31,
2023, filed with the Securities and Exchange Commission (“SEC”), which is available on the SEC’s website, www.sec.gov,
and in subsequent filings made by NLS with the SEC, including under the heading “Risk Factors” in NLS’s registration
statement on Form F-4, filed with the SEC on December 27, 2024.

<div align='center'>4</div>

No Offer or Solicitation

This communication is not intended to and shall
not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or
approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by
means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Additional Information about the Transaction and
Where to Find It

In connection with the proposed transaction, NLS
has filed a Registration Statement on Form F-4, including a proxy statement/prospectus, with the SEC. NLS may also file other relevant
documents with the SEC regarding the proposed transaction. This document is not a substitute for the proxy statement/prospectus or any
other document that NLS may file with the SEC. The proxy statement (if and when available) will be mailed or delivered to shareholders
of NLS and Kadimastem. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS
THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR